Novo Nordisk’s Diabetes Pill Gets EU Label Extension For Heart Benefits
PositiveHealth

Novo Nordisk's diabetes pill Rybelsus has received an EU label extension to officially include its heart benefits. This approval enhances its treatment profile for type 2 diabetes.
Editor’s Note: This matters because it not only expands the therapeutic options for patients with type 2 diabetes but also highlights the importance of cardiovascular health in diabetes management.
— Curated by the World Pulse Now AI Editorial System